BioLineRx Operating Margin vs. Net Income
| BLRX Stock | USD 2.88 0.01 0.35% |
BioLineRx Operating Profit Margin |
|
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.62 | 0.78 |
|
|
For BioLineRx profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioLineRx to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioLineRx utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioLineRx's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioLineRx over time as well as its relative position and ranking within its peers.
BioLineRx | Build AI portfolio with BioLineRx Stock |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioLineRx. If investors know BioLineRx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioLineRx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.00) | Revenue Per Share | Quarterly Revenue Growth (0.94) | Return On Assets | Return On Equity |
The market value of BioLineRx is measured differently than its book value, which is the value of BioLineRx that is recorded on the company's balance sheet. Investors also form their own opinion of BioLineRx's value that differs from its market value or its book value, called intrinsic value, which is BioLineRx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioLineRx's market value can be influenced by many factors that don't directly affect BioLineRx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioLineRx's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioLineRx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioLineRx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioLineRx Net Income vs. Operating Margin Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioLineRx's current stock value. Our valuation model uses many indicators to compare BioLineRx value to that of its competitors to determine the firm's financial worth. BioLineRx is rated third in operating margin category among its peers. It is number one stock in net income category among its peers . At this time, BioLineRx's Operating Profit Margin is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the BioLineRx's earnings, one of the primary drivers of an investment's value.BioLineRx Net Income vs. Operating Margin
Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
BioLineRx |
| = | (7.58) % |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
BioLineRx |
| = | (9.22 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
BioLineRx Net Income Comparison
BioLineRx is currently under evaluation in net income category among its peers.
BioLineRx Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioLineRx, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioLineRx will eventually generate negative long term returns. The profitability progress is the general direction of BioLineRx's change in net profit over the period of time. It can combine multiple indicators of BioLineRx, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 18.6 M | 11.8 M | |
| Operating Income | -18.4 M | -19.3 M | |
| Income Before Tax | -8.3 M | -8.7 M | |
| Total Other Income Expense Net | 10.1 M | 10.6 M | |
| Net Loss | -8.3 M | -8.7 M | |
| Net Loss | -24.3 M | -25.6 M | |
| Income Tax Expense | 900.00 | 945.00 | |
| Net Loss | -8.3 M | -8.7 M | |
| Interest Income | 2.1 M | 1.1 M | |
| Net Interest Income | -6.6 M | -6.2 M | |
| Change To Netincome | 3.8 M | 4 M | |
| Net Loss | (0.01) | (0.01) | |
| Income Quality | 5.47 | 5.75 | |
| Net Income Per E B T | 0.96 | 1.09 |
BioLineRx Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioLineRx. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioLineRx position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioLineRx's important profitability drivers and their relationship over time.
BioLineRx Earnings Estimation Breakdown
The calculation of BioLineRx's earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of BioLineRx is estimated to be -0.19875 with the future projection ranging from a low of -0.24 to a high of -0.1575. Please be aware that this consensus of annual earnings estimates for BioLineRx is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-0.24 Lowest | Expected EPS | -0.16 Highest |
BioLineRx Earnings Projection Consensus
Suppose the current estimates of BioLineRx's value are higher than the current market price of the BioLineRx stock. In this case, investors may conclude that BioLineRx is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and BioLineRx's stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 2 | 49.0% | -0.2259 | -0.19875 | -6.0 |
BioLineRx Earnings per Share Projection vs Actual
Actual Earning per Share of BioLineRx refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering BioLineRx predict the company's earnings will be in the future. The higher the earnings per share of BioLineRx, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.BioLineRx Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as BioLineRx, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of BioLineRx should always be considered in relation to other companies to make a more educated investment decision.BioLineRx Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact BioLineRx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-13 | 2025-09-30 | -0.54 | -0.2259 | 0.3141 | 58 | ||
2025-08-14 | 2025-06-30 | -0.53 | -1.0184 | -0.4884 | 92 | ||
2025-05-27 | 2025-03-31 | -1.06 | -1.5006 | -0.4406 | 41 | ||
null | null | null | null | null | 0 | ||
2024-11-25 | 2024-09-30 | -4.4 | -0.0728 | 4.3272 | 98 | ||
2024-08-15 | 2024-06-30 | -0.14 | 0.0061 | 0.1461 | 104 | ||
2024-05-28 | 2024-03-31 | -0.29 | -0.01 | 0.28 | 96 | ||
2024-03-28 | 2023-12-31 | -0.16 | -0.15 | 0.01 | 6 | ||
2023-11-20 | 2023-09-30 | -0.21 | -0.01 | 0.2 | 95 | ||
2023-08-30 | 2023-06-30 | -0.11 | -0.3 | -0.19 | 172 | ||
2023-05-25 | 2023-03-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2023-03-22 | 2022-12-31 | -0.09 | -0.09 | 0.0 | 0 | ||
2022-11-15 | 2022-09-30 | -0.16 | -0.01 | 0.15 | 93 | ||
2022-09-30 | 2022-06-30 | -0.11 | -0.15 | -0.04 | 36 | ||
2022-05-25 | 2022-03-31 | -0.09 | -0.15 | -0.06 | 66 | ||
2022-03-16 | 2021-12-31 | -0.14 | -0.1 | 0.04 | 28 | ||
2021-12-09 | 2021-09-30 | -0.16 | -0.15 | 0.01 | 6 | ||
2021-08-18 | 2021-06-30 | -0.15 | -0.15 | 0.0 | 0 | ||
2021-05-26 | 2021-03-31 | -0.15 | -0.3 | -0.15 | 100 | ||
2021-02-23 | 2020-12-31 | -0.28 | -0.6 | -0.32 | 114 | ||
2020-11-23 | 2020-09-30 | -0.35 | -0.3 | 0.05 | 14 | ||
2020-08-06 | 2020-06-30 | -0.73 | -0.45 | 0.28 | 38 | ||
2020-05-20 | 2020-03-31 | -0.82 | -0.6 | 0.22 | 26 | ||
2020-03-12 | 2019-12-31 | -0.66 | -0.9 | -0.24 | 36 | ||
2019-11-19 | 2019-09-30 | -0.5 | -0.45 | 0.05 | 10 | ||
2019-08-06 | 2019-06-30 | -0.63 | -0.6 | 0.03 | 4 | ||
2019-05-14 | 2019-03-31 | -0.75 | -0.75 | 0.0 | 0 | ||
2019-03-28 | 2018-12-31 | -1.39 | -0.6 | 0.79 | 56 | ||
2018-11-08 | 2018-09-30 | -0.82 | -0.9 | -0.08 | 9 | ||
2018-08-13 | 2018-06-30 | -0.9 | -0.75 | 0.15 | 16 | ||
2018-05-22 | 2018-03-31 | -1.05 | -0.9 | 0.15 | 14 | ||
2018-03-06 | 2017-12-31 | -0.94 | -1.2 | -0.26 | 27 | ||
2017-11-21 | 2017-09-30 | -0.82 | -1.05 | -0.23 | 28 | ||
2017-08-08 | 2017-06-30 | -0.82 | -0.75 | 0.07 | 8 | ||
2017-05-25 | 2017-03-31 | -0.85 | -1.2 | -0.35 | 41 | ||
2017-03-23 | 2016-12-31 | -1.2 | -1.05 | 0.15 | 12 | ||
2016-11-22 | 2016-09-30 | -1.1 | -1.2 | -0.1 | 9 | ||
2016-08-11 | 2016-06-30 | -1.1 | -1.05 | 0.05 | 4 | ||
2016-05-17 | 2016-03-31 | -1.15 | -0.96 | 0.19 | 16 | ||
2016-03-10 | 2015-12-31 | -0.9 | -1.05 | -0.15 | 16 | ||
2015-11-16 | 2015-09-30 | -1.25 | -0.45 | 0.8 | 64 | ||
2015-08-20 | 2015-06-30 | -1.12 | -1.35 | -0.23 | 20 | ||
2015-05-18 | 2015-03-31 | -0.9 | -1.5 | -0.6 | 66 | ||
2015-03-23 | 2014-12-31 | -3.6 | -0.13 | 3.47 | 96 | ||
2014-11-10 | 2014-09-30 | -2.47 | -0.3 | 2.17 | 87 | ||
2014-08-06 | 2014-06-30 | -1.65 | -1.8 | -0.15 | 9 | ||
2014-05-20 | 2014-03-31 | -1.57 | -1.5 | 0.07 | 4 | ||
2014-03-17 | 2013-12-31 | -2.25 | -3.0 | -0.75 | 33 | ||
2013-11-13 | 2013-09-30 | -2.62 | -3.0 | -0.38 | 14 | ||
2013-08-06 | 2013-06-30 | -1.65 | -2.85 | -1.2 | 72 | ||
2013-05-07 | 2013-03-31 | -1.95 | -0.3 | 1.65 | 84 | ||
2013-03-12 | 2012-12-31 | -4.2 | -4.5 | -0.3 | 7 | ||
2012-11-14 | 2012-09-30 | -3.45 | -6.0 | -2.55 | 73 | ||
2012-08-15 | 2012-06-30 | -3.75 | -2.4 | 1.35 | 36 |
Use BioLineRx in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioLineRx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioLineRx will appreciate offsetting losses from the drop in the long position's value.BioLineRx Pair Trading
BioLineRx Pair Trading Analysis
The ability to find closely correlated positions to BioLineRx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioLineRx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioLineRx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioLineRx to buy it.
The correlation of BioLineRx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioLineRx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioLineRx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioLineRx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your BioLineRx position
In addition to having BioLineRx in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Alternative Currency ETFs Thematic Idea Now
Alternative Currency ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Alternative Currency ETFs theme has 103 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Currency ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.